

1 **Paired methods to measure biofilm killing and removal: a case study with Penicillin G**  
2 **treatment of *Staphylococcus aureus* biofilm**

3 **Running title:** Biofilm kill/removal measurements

4

5 Dominik Ausbacher<sup>1</sup>, Lindsey Lorenz, Betsey Pitts, Philip S. Stewart, Darla M. Goeres\*

6 *Center for Biofilm Engineering, Montana State University, Bozeman, United States*

7

8 \* Corresponding author at: Center for Biofilm Engineering, 366 Barnard Hall, Montana State  
9 University, Bozeman, MT 59717, United States. Tel.: +1 406 994 4770, E-mail address:

10 darla\_g@biofilm.montana.edu

11

12

13

14

15 <sup>1</sup> Present address: Hospital Pharmacy of North Norway Trust, N-9038 Tromsø, Norway.

16

17

18 **Significance and impact of the study**

19 Biofilms are tolerant to antimicrobial treatments and can lead to severe infections. Finding new anti-  
20 biofilm strategies and understanding their mode-of-action is therefore of high importance. Historically,  
21 antimicrobial testing has focused on measuring efficacy. While kill data are undeniably important,  
22 measuring biofilm dispersal provides equally useful information. Starting with biofilm grown in the  
23 same reactor, we paired assessment of biofilm removal using a new treatment- flow-cell and real-time  
24 microscopy with kill data collected using the single tube method (ASTM method E2871). Pairing these  
25 two methods revealed efficient biofilm removal properties of Penicillin G which were not detected  
26 during efficacy testing.

27

28 **Abstract**

29 Biofilms are microbial aggregates that show high tolerance to antibiotic treatments *in vitro* and *in vivo*.  
30 Killing and removal are both important in biofilm control, therefore methods that measure these two  
31 mechanisms were evaluated in a parallel experimental design. Kill was measured using the single tube  
32 method (ASTM method E2871) and removal was determined by video microscopy and image analysis  
33 using a new treatment flow cell. The advantage of the parallel test design is that both methods used  
34 biofilm covered coupons harvested from a CDC biofilm reactor, a well-established and standardized  
35 biofilm growth method. The control *Staphylococcus aureus* biofilms increased by 0.6 logs during a 3 h  
36 contact time to medium lacking antibiotic. Efficacy testing showed biofilms exposed to 400  $\mu\text{mol l}^{-1}$   
37 penicillin G decreased by only 0.3 logs. Interestingly, time-lapse confocal scanning laser microscopy  
38 revealed that penicillin G treatment dispersed the biofilm despite being an ineffective killing agent. In  
39 addition, no biofilm removal was detected when assays were performed in 96-well plates. These  
40 results illustrate that biofilm behavior and impact of treatments can vary substantially when assayed by

41 different methods. Measuring both killing and removal with well-characterized methods will be crucial  
42 for the discovery of new anti-biofilm strategies.

43

44

45 **Keywords:**

46 Treatment-flow-cell

47 Single tube method

48 Biofilm

49 Penicillin

50 *Staphylococcus aureus*

51 Confocal laser scanning microscopy

52 Antibiotic efficacy testing

## 53 **Introduction**

54           Microbial biofilms exhibit increased tolerance to treatment with disinfectants and antibiotics,  
55 and often, only combinations of chemical and physical measures can reduce viable cell numbers and/or  
56 remove biofilm from surfaces . Killing viable cells is the focus of traditional antibiotic therapy,  
57 although, removal of the matrix and/or prevention of initial attachment events are potentially important  
58 mechanisms in the battle to control biofilm. Currently for a medical device colonized with biofilm,  
59 replacement is often the only option to reestablish proper functionality resulting in high socioeconomic  
60 burdens for patients and health care systems (Wilkins *et al.*, 2014).

61           *In vivo*, biofilms grow in a diverse range of conditions and *in vitro* biofilms must therefore be  
62 studied using laboratory systems that model various conditions. Static systems, such as well-plates,  
63 grow biofilm under batch conditions (no replenishment of the nutrients) and minimal fluid shear. In a  
64 dynamic system, the nutrients are continuously replenished, and the fluid shear may vary from laminar  
65 to turbulent flow, depending upon the reactor system (Crusz *et al.*, 2012). Flow cells are a useful tool  
66 for facilitating detailed investigations of initial attachment events and biofilm removal, both important  
67 aspects of biofilm control strategies. The preference for using dynamic assay systems is reflected by  
68 US FDA regulatory guidelines for testing medical devices containing antimicrobials (Food and Drug  
69 Administration, 2015).

70           ASTM method E2871-13, a biofilm efficacy test generally known as the single tube method,  
71 and ASTM method E2562-17 which describes how to grow a biofilm in the CDC biofilm reactor  
72 (ASTM International, 2013; ASTM International, 2017) were developed and statistically validated for  
73 measuring the efficacy of biocides against biofilm bacteria. The CDC biofilm reactor design allows for  
74 flexibility regarding biofilm growth conditions and sampling regimes due to the placement of three  
75 removable coupons in each of eight rods (Goeres *et al.*, 2005; Buckingham-Meyer *et al.*, 2007). By

76 design, the single-tube method only measures the efficacy of biocides and antibiotics against biofilm.  
77 The single tube method is a static test system and does not provide information on biofilm removal. To  
78 address this limitation of the single tube method, the treatment-flow-cell (FC310; Biosurface  
79 Technologies, Bozeman, USA) was designed as a complementary new tool (Fig. 1). The treatment-  
80 flow-cell can be used to assess biofilm removal in real time that results from treatment of a mature  
81 biofilm grown on coupons harvested from the CDC reactor. Using both, the single tube method and the  
82 treatment flow cell in parallel allows a researcher to assess the kill and/or removal that results when a  
83 biofilm is exposed to an antibiotic or biocide, thereby providing key insights into the mechanism of  
84 action.

85 This paper highlights the advantages of combining kill and removal biofilm assays when  
86 finding new biofilm control strategies. Our treatment-flow-cell experiments, carried out in combination  
87 with the single tube method, allowed us to identify the effective biofilm removal properties of  
88 Penicillin G (Pen G) against a mature *Staphylococcus aureus* (*S. aureus*) biofilm. To our knowledge,  
89 this antibiofilm property of Pen G has not been reported yet.

90

## 91 **Results and Discussion**

### 92 *Growth performance and Pen G susceptibility of planktonic S. aureus AH2547*

93 Planktonic *S. aureus* AH2547 had a generation time of 25 min, which lies in the normal  
94 bacterial proliferation range despite the metabolic burden of GFP expression (Domingue *et al.*, 1996).  
95 A concentration of 0.15  $\mu\text{mol l}^{-1}$  Pen G inhibited growth of the strain (Fig. 2A). We detected a  
96 difference in growth curve development for the treated versus control bacteria after 90 minutes of  
97 incubation (Fig. 2A). Due to the mode-of-action of Pen G no rapid bactericidal effect was detected,

98 similar to previous experiments involving Pen G and the *S. aureus* strain ATCC 25923 (Ausbacher *et*  
99 *al.*, 2014).

#### 100 *Treatment-flow-cell biofilm experiments and image analysis*

101 Coupons containing *S. aureus* AH2547 biofilm grown in the CDC reactor were collected for either  
102 efficacy testing according to the single tube method or placement into the treatment-flow-cell to assess  
103 removal. This allowed for the parallel measurement of biofilm killing and biofilm removal eliminating  
104 any experiment-to-experiment variability that is possible if the biofilm had been grown in different  
105 reactors on different days. Our microscopy studies showed that treatment with full-strength TSB in the  
106 treatment-flow-cell did not affect *S. aureus* biofilms. However, we observed a slight decrease of  
107 fluorescence intensity over time when performing image analysis. This can be attributed to bleaching  
108 from repeated laser light exposure (Fig. 2B, controls of experiments 1-3). Images of the untreated  
109 control coupons showed no removal events (Fig. 2C and supplementary videos S1-2). We used 400  
110  $\mu\text{mol l}^{-1}$  of Pen G during our biofilm experiments based upon data from previous studies where equally  
111 high concentrations had only a low to moderate impact on biofilm viability (Ausbacher *et al.*, 2014;  
112 Manner *et al.*, 2015). Exposing the biofilm to Pen G first caused erosion of the biofilm and finally  
113 resulted in complete removal of the biofilm after 40 min, 100 min or 120 min (Fig. 2 B-C and  
114 supplementary video S2). Image analysis showed a 60% to 100% biofilm removal within a 90 minute  
115 time period. In contrast, growth curves of untreated controls and Pen G treated planktonic bacteria  
116 followed each other for 90 min due to the antibiotic's dependence on proliferating bacteria (Fig. 2A).  
117 Even though there is a discrepancy in Pen G concentration, it has been reported that increased  
118 penicillin dosing does not necessarily impact the effect of  $\beta$ -lactam antibiotics (Van Herendael *et al.*,  
119 2012). We conducted our experiments in full strength TSB and the flow of nutrients facilitated  
120 hydrodynamic interactions. The increased mass transfer, higher shear forces and the additional  
121 influence of Pen G, may therefore account for the substantial biofilm removal, which represents a

122 cohesive material failure (Brindle *et al.*, 2011). Physicochemical interaction of Pen G with the biofilm  
123 is plausible, considering that Pen G has surface active properties and is capable of forming micelles  
124 (Thakkar *et al.*, 1971). Of note, Brindle *et al* have made similar observations when testing an urea  
125 treatment, which in itself is not antimicrobial, against *S. epidermidis* biofilms (Brindle *et al.*, 2011). In  
126 the study, urea removed biofilm within minutes when applied in conjunction with flow whereas a static  
127 soak and subsequent fluid shear challenge did not result in biofilm removal. Besides urea, the anionic  
128 surfactant SDS, chloride and chlorine-releasing agents have also been reported as having good removal  
129 properties when *Pseudomonas aeruginosa* biofilms were treated (Chen *et al.*, 2000). The dispersal of  
130 the *S. aureus* biofilm might however be the result of a synergistic combination of bacteria/matrix  
131 response to the presence of Pen G and demonstrates the benefits of testing in a system with  
132 hydrodynamics.

133

#### 134 *Single tube method*

135 It was advantageous that we could investigate the effect of Pen G on biofilms collected from the  
136 same reactor as those used in the treatment-flow cell due to the 24 available coupons in the CDC  
137 biofilm reactor. Pen G had a bacteriostatic effect on the biofilm bacteria with a difference of 0.3 log  
138 units between 1 and 3 hours of treatment (Fig. 3A). In contrast, bacteria in the untreated control  
139 biofilms proliferated under these conditions with a log increase of 0.6.

140 The viable plate count data collected during the single tube method experiments suggest that the  
141 observed biofilm removal cannot be explained by a decrease in bacterial viability. Data from our OD<sub>600</sub>  
142 measurements (Fig. 2A) illustrate that Pen G, whose efficacy depends on dividing bacteria, does not  
143 have an instant effect on bacteria compared to what is generally known from rapidly acting biocides.

144

145 96-well plate biofilm assay

146 In order to check the treatment behavior of AH2547 biofilms in other assay systems we chose a  
147 96-well plate format. The 96-well plate is a favorable tool for drug screening and is commonly used by  
148 many laboratories for detecting potential anti-biofilm compounds. In this static assay system we tested  
149 if Pen G treatment led to fluorescence loss due to biofilm removal and/or cell lysis. The well-plate  
150 experiments did not result in substantial biofilm removal or loss in fluorescence after exchange of the  
151 planktonic phase (Fig. 3B). In contrast to the treatment flow cell, increased mass transfer and shear  
152 forces are absent in a 96 well-plate assay, similar to the single tube method. Lack of Pen G potency in  
153 equally high concentrations against biofilms of various *S. aureus* strains in well-plate based assays has  
154 been reported by others groups (Amorena *et al.*, 1999; Pettit *et al.*, 2009; Ausbacher *et al.*, 2014;  
155 Manner *et al.*, 2015). This suggests that the sole presence of 400  $\mu\text{mol l}^{-1}$  of Pen G does not trigger  
156 biofilm removal. *S. aureus* biofilms grown in a 96-well format in the presence of high concentrations of  
157 Pen G can provoke protein expression for the increased energy supply for strengthening of the  
158 proteoglycan (Savijoki *et al.*, 2016). In addition to this defense strategy, Pen G is suspected to induce  
159 dormancy and thus support biofilm sustainability (Savijoki *et al.*, 2016). Further studies are needed to  
160 fully elucidate the molecular bases of the biofilm dispersing mechanism of Pen G on *S. aureus*  
161 biofilms.

162 We demonstrated the usefulness of the treatment-flow-cell for visualizing biofilm removal in  
163 real-time. The ability to use coupons collected from the same CDC reactor for both the treatment flow  
164 cell and single tube method efficacy test allows for a more comprehensive evaluation of the  
165 mechanisms of action of potential antibiofilm treatments. Furthermore, our case study provides a good  
166 example of the importance of using multiple methods to reveal potent removal properties of Pen G,  
167 which has not been reported previously. The implementation of different test regimens can therefore be  
168 pivotal in identifying new biofilm control strategies.



## 169 **Material and Methods**

### 170 *Bacterial strain*

171 We used the green fluorescent protein (GFP) expressing *S. aureus* strain AH2547 which and  
172 contains the GFP-expressing plasmid pCM29 (Pang *et al.*, 2010) kindly provided by Dr. Alex Horswill.

173

### 174 *Planktonic growth analysis and Pen G susceptibility*

175 Overnight cultures of *S. aureus* AH2547 were prepared in TSB, supplemented with  
176 chloramphenicol (10 µg/mL) for plasmid retention. Growth analyses of AH2547 were conducted in a  
177 50 mL broth volume, supplemented with chloramphenicol as described above. The OD<sub>600</sub> values of  
178 aliquots were measured every 30 min and plated on TSA agar for CFU/mL determination. Generation  
179 time was calculated from the log-phase of AH2547 proliferation. Growth curves of treated and  
180 untreated bacteria were determined with a Biotek Synergy HT microplate reader (Biotek Instruments  
181 Inc., Winooski, VT, USA) in a 96-well plate format as described by Ausbacher *et al.* (Ausbacher *et al.*,  
182 2014).

183

### 184 *Formation of 48 h biofilms in CDC reactor*

185 Biofilms were formed on glass coupons (diameter 1.27 cm) according to a modification of  
186 ASTM Method E2562-17 and Buckingham-Meyer *et al.* (Buckingham-Meyer *et al.*, 2007; ASTM  
187 International, 2017). In brief, a CDC reactor containing 500 ml full strength TSB and chloramphenicol  
188 (10 µg/mL) was inoculated with 1 mL of a 10<sup>9</sup> CFU/mL overnight GFP *S. aureus* culture grown in full  
189 strength TSB supplemented with 10 mg/mL chloramphenicol for plasmid retention. The biofilm grew

190 in batch conditions at 37°C, 125 rpm for 24 h. Continuous flow of one-tenth TSB was applied  
191 subsequently for another 24 h at 37°C and 125 rpm before coupons were sampled from the reactor.

192

### 193 *Treatment-flow-cell and confocal microscopy*

194 Coupons were transferred to the treatment-flow-cell (model FC310; Biosurface Technologies,  
195 Bozeman, Mt, USA) with the low shear side up (side that faced the reactor wall). A flow of full  
196 strength TSB (2 ml/min, 37°C) was applied for three minutes to stabilize the system and for adjusting  
197 instrument settings. Untreated controls were treated with TSB. The penicillin G treatment (400  $\mu\text{mol l}^{-1}$   
198 Pen G in TSB) was applied after the system was stable. The pH of TSB was not affected by the  
199 presence of the antibiotic (Table 1). Images were acquired of the bright field and GFP channel using a  
200 Leica SP5 confocal laser scanning microscope. The z-stack step size was set to 10  $\mu\text{mol l}^{-1}$ . Movie  
201 generation was carried out with IMARIS® (Bitplane) and image analysis with MetaMorph®  
202 (Molecular Devices). The FIJI software bundle was used for generating overlay images (Schindelin *et*  
203 *al.*, 2012).

204

### 205 *Single tube method for treatment efficacy testing*

206 ASTM Method E2871, generally known as the single tube method, was used to quantitatively  
207 measure the log reduction in viable biofilm cells exposed to a Pen G for 1 h, 2 h and 3 h (ASTM  
208 International, 2013). Briefly, coupons containing *S. aureus* biofilm were removed from the CDC  
209 reactor, rinsed and then transferred to 50 ml conical tubes with tweezers. Subsequently, 4 mL of TSB  
210 or 400  $\mu\text{mol l}^{-1}$  Pen G prepared in TSB were carefully added to the tubes. The tubes were incubated at  
211 37°C under static conditions. At each specific time point, 36 mL D/E broth was added and the biofilm  
212 was disaggregated by sonication and vortexing according to ASTM E2871. All tubes were kept on wet

213 ice and each sample was diluted immediately to neutralize the Pen G. The diluted samples were drop  
214 plated on TSA plates, incubated overnight at 37°C and enumerated.

215

#### 216 *Biofilm formation and treatment in 96-well plates*

217 We performed a similar static assay in 96-well plates to investigate if a comparable effect was  
218 found in another test system commonly used in biofilm research. Biofilms were formed and treated as  
219 described by Ausbacher *et al.* (Ausbacher *et al.*, 2014). After treatment, the biofilm GFP fluorescence  
220 was measured using a BioTek Synergy H1 (Biotek Instruments Inc., Winooski, VT, USA), multi-mode  
221 plate reader.

222

#### 223 *Statistics*

224 The Students t-test was performed using the quantitative data from the single-tube method and  
225 96-well plate assays using SigmaPlot 13.0.

226

#### 227 *Acknowledgements*

228 We thank Dr. Alex Horswill for providing the *S. aureus* strain AH2547. This work was  
229 supported by a personal overseas grant to D.A. and the “*fellesløftet*” grant 214493/F20 by the Research  
230 Council of Norway.

231

#### 232 *Conflict of Interest*

233 No conflict of interest is declared.

234 **References**

- 235 Amorena, B., Gracia, E., Monzon, M., Leiva, J., Oteiza, C., Perez, M., Alabart, J.L. and Hernandez-  
236 Yago, J. (1999) Antibiotic susceptibility assay for *Staphylococcus aureus* in biofilms developed *in*  
237 *vitro*. *J Antimicrob Chemother* **44**, 43-55.
- 238 ASTM E2871-13, Standard Test Method for Evaluating Disinfectant Efficacy against *Pseudomonas*  
239 *aeruginosa* Biofilm Grown in CDC Biofilm Reactor using Single Tube Method, ASTM International,  
240 West Conshohocken, PA., 2013, www.astm.org.
- 241 ASTM E2562-17, Standard Test Method for Quantification of *Pseudomonas aeruginosa* Biofilm  
242 Grown with High Shear and Continuous Flow using CDC Biofilm Reactor, ASTM International, West  
243 Conshohocken, PA, 2017, www.astm.org.
- 244 Ausbacher, D., Fallarero, A., Kujala, J., Määttänen, A., Peltonen, J., Strøm, M.B. and Vuorela, P.M.  
245 (2014) *Staphylococcus aureus* biofilm susceptibility to small and potent  $\beta^{2,2}$ -amino acid derivatives.  
246 *Biofouling* **30**, 81-93.
- 247 Brindle, E.R., Miller, D.A. and Stewart, P.S. (2011) Hydrodynamic deformation and removal of  
248 *Staphylococcus epidermidis* biofilms treated with urea, chlorhexidine, iron chloride, or DispersinB.  
249 *Biotechnol Bioeng* **108**, 2968-2977.
- 250 Buckingham-Meyer, K., Goeres, D.M. and Hamilton, M.A. (2007) Comparative evaluation of biofilm  
251 disinfectant efficacy tests. *J Microbiol Methods* **70**, 236-244.
- 252 Chen, X. and Stewart, P.S. (2000) Biofilm removal caused by chemical treatments. *Water Research* **34**,  
253 4229-4233.
- 254 Crusz, S.A., Popat, R., Rybtke, M.T., Camara, M., Givskov, M., Tolker-Nielsen, T., Diggle, S.P. and  
255 Williams, P. (2012) Bursting the bubble on bacterial biofilms: a flow cell methodology. *Biofouling* **28**,  
256 835-842.
- 257 Domingue, G., Costerton, J.W. and Brown, M.R. (1996) Bacterial doubling time modulates the effects  
258 of opsonisation and available iron upon interactions between *Staphylococcus aureus* and human  
259 neutrophils. *FEMS Immunol Med Microbiol* **16**, 223-228.
- 260 Food and Drug Administration (27-8-2015) Draft guidance for industry and FDA staff - premarket  
261 notification [510(k)] submissions for medical devices that include antimicrobial agents, July 2007.
- 262 Goeres, D.M., Loetterle, L.R., Hamilton, M.A., Murga, R., Kirby, D.W. and Donlan, R.M. (2005)  
263 Statistical assessment of a laboratory method for growing biofilms. *Microbiology (Reading, U K)* **151**,  
264 757-762.
- 265 Manner, S., Vahermo, M., Skogman, M.E., Krogerus, S., Vuorela, P.M., Yli-Kauhaluoma, J., Fallarero,  
266 A. and Moreira, V.M. (2015) New derivatives of dehydroabietic acid target planktonic and biofilm  
267 bacteria of *Staphylococcus aureus* and effectively disrupt bacterial membrane integrity. *Eur J Med*  
268 *Chem* **102**, 68-79.

- 269 Pang, Y.Y., Schwartz, J., Thoendel, M., Ackermann, L.W., Horswill, A.R. and Nauseef, W.M. (2010)  
270 agr-Dependent Interactions of *Staphylococcus aureus* USA300 with Human Polymorphonuclear  
271 Neutrophils. *J Innate Immun* **2**, 546-559.
- 272 Pettit, R.K., Weber, C.A. and Pettit, G.R. (2009) Application of a high throughput Alamar blue biofilm  
273 susceptibility assay to *Staphylococcus aureus* biofilms. *Ann Clin Microbiol Antimicrob* **8:28**.
- 274 Savijoki, K., Skogman, M., Fallarero, A., Nyman, T.A., Sukura, A., Vuorela, P. and Varmanen, P.  
275 (2016) Penicillin G increases the synthesis of a suicidal marker (CidC) and virulence (HlgBC) proteins  
276 in *Staphylococcus aureus* biofilm cells. *Int J Med Microbiol* **306**, 69-74.
- 277 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S.,  
278 Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J.Y., White, D.J., Hartenstein, V., Eliceiri, K.,  
279 Tomancak, P. and Cardona, A. (2012) Fiji: an open-source platform for biological-image analysis. *Nat*  
280 *Methods* **9**, 676-682.
- 281 Thakkar, A.L. and Wilham, W.L. (1971) Self-association of benzylpenicillin in aqueous solution:  
282 proton nuclear magnetic resonance study. *J Chem Soc D*, 320-322.
- 283 Van Herendael, B., Jeurissen, A., Tulkens, P.M., Vlieghe, E., Verbrugghe, W., Jorens, P.G. and Ieven,  
284 M. (2-7-2012) Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-  
285 lactams and vancomycin? *Annals of Intensive Care* **2**, 22.
- 286 Wilkins, M., Hall-Stoodley, L., Allan, R.N. and Faust, S.N. (2014) New approaches to the treatment of  
287 biofilm-related infections. *J Infect* **69 Suppl 1**, S47-S52.  
288  
289
- 290

291 **Supporting information**

292 *S. aureus* biofilm containing coupons, sampled from a CDC biofilm reactor, were transferred to the  
293 treatment-flow-cell with the low shear side up. TSB (2 ml/min, 37°C) was applied for three minutes to  
294 stabilize the system and continued for our untreated controls. Once stabilized, the treated coupons were  
295 exposed to 400 µmol l<sup>-1</sup> Pen G in flowing TSB. Images were acquired with a Leica SP5 confocal laser  
296 scanning microscope using transmission and GFP channels. The z-stack step size was set to 10 µm and  
297 movie generation was carried out with IMARIS® (Bitplane, South Windsor, CT, USA).

298

299 **Video S1:** Video microscopy of experiment 2 – Pen G 400 µmol l<sup>-1</sup> (GFP and brightfield channels)

300 **Video S2:** Video microscopy of experiment 2 – untreated control (GFP and brightfield channels)

301 **Figure legends**

302

303 **Fig. 1** Cross section and top view of the treatment flow cell illustrating coupon location, flow in- and  
304 outlet and mounting notches for attachment to the microscope stage. The treatment flow cell is sealed  
305 by a 25 mm cover slip, which is located under the silicon gasket, after the cap had been screwed on the  
306 bottom part of the cell. Barb ports accommodate 3 mm tubing for inlet and outlet (schematic adapted  
307 with permission from Biosurface Technologies Corp.).

308

309 **Fig. 2** Behavior of planktonic *S. aureus*, image analysis data and CLSM overlay images after real-time  
310 image acquisition of treated *S. aureus* biofilms. (A) Pen G ( $0,15 \mu\text{mol l}^{-1}$ ) treated and untreated  
311 planktonic *S. aureus* over an incubation period of 24 h, Pen G  $400 \mu\text{mol l}^{-1}$  (●) and untreated control  
312 (○). (B) Image analysis of untreated *S. aureus* biofilms and after treatment with  $400 \mu\text{mol l}^{-1}$  of Pen G  
313 in three independent experiments. Experiment 1-Pen G (●), experiment 1 – control (○), experiment 2-  
314 Pen G (▲), experiment 2-control (Δ), experiment 3-Pen G (■), experiment 3-control (□). For clarity,  
315 data points of each experiment were connected. (C) GFP-brightfield overlay images of control biofilms  
316 and Pen G treated biofilms at experiment start (0 min), start of erosion (40 min) and during dispersion  
317 phase (85 – 110 min). Scale bars represent  $200 \mu\text{mol l}^{-1}$ . Movies of Pen G treated and untreated  
318 biofilms are available as supplemental information in the online version of this article (videos S1-S2).


319

320 **Fig. 3** Quantification of the Pen G impact on *S. aureus* biofilms. (A) Quantification of viable cells of  
321 mature biofilms from a CDC biofilm reactor by using the single-tube method. (□) untreated control,  
322 (■)  $400 \mu\text{mol l}^{-1}$  Pen G. Asterisk indicates significant difference,  $p < 0.05$  (Student's t-test). (B)

323 Quantification of 18 h biofilms in 96-well plates utilizing GFP fluorescence of *S. aureus*. Treatment of  
324 biofilms for 1 – 3 h were followed by exchange of the planktonic phase, which did not lead to removal  
325 of biofilms in 96-well plates. Results display the mean  $\pm$  SD of three independent experiments.




326 **Figure 1**



327


328 **Figure 2**



329

330

331 **Figure 3**



332